Position in NUVL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$204,900
+$3,720 QoQ
Shares Held
2,000
0.0% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NUVL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PORTLAND INVESTMENT COUNSEL INC. holds $5,667,950 across 9 Biotechnology names. NUVL ranks #6 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TLX |
Telix Pharmaceuticals Ltd
|
266,200 | $2,547,534 | |
| 2 | ONC |
BeOne Medicines Ltd.
|
3,000 | $890,910 | |
| 3 | OLMA |
Olema Pharmaceuticals, Inc.
|
50,000 | $745,500 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
654 | $505,306 | |
| 5 | IOVA |
Iovance Biotherapeutics, Inc.
|
130,000 | $456,300 | |
| 6 | NUVL |
Nuvalent, Inc.
This page
|
2,000 | $204,900 | |
| 7 | ARVN |
Arvinas, Inc.
|
14,000 | $148,400 | |
| 8 | RLAY |
Relay Therapeutics, Inc.
|
10,000 | $99,500 |
All Filings in NUVL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $204,900 | 2,000 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $201,180 | 2,000 | Shares | Sole | 2026-02-12 | |
| 2024-09-30 | $204,600 | 2,000 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||